2 results
Approved WMOCompleted
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
Approved WMORecruiting
To study wether a biodressing impregnated with polyhexamethylene biguanide in the treatment of spoke injuries in children could give a reduction in pain during the treatment compared to the standard treatment with wound dressing impregnated with